Search Results

You are looking at 1 - 1 of 1 items for

  • Author: D Morganstein x
Clear All Modify Search
C E Higham Department of Endocrinology, Christie Hospital NHS Foundation Trust, Manchester, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

Search for other papers by C E Higham in
Google Scholar
PubMed
Close
,
A Olsson-Brown The Clatterbridge Cancer Centre, Bebbington, Wirral, UK
The University of Liverpool, Brownlow Hill, Liverpool, UK

Search for other papers by A Olsson-Brown in
Google Scholar
PubMed
Close
,
P Carroll Department of Endocrinology, Guy’s & St. Thomas’ NHS Foundation Trust, London, UK

Search for other papers by P Carroll in
Google Scholar
PubMed
Close
,
T Cooksley Department of Acute Medicine, UHSM and Christie Hospital NHS Foundation Trust, Manchester, UK

Search for other papers by T Cooksley in
Google Scholar
PubMed
Close
,
J Larkin Skin Unit, Royal Marsden Hospital, London, UK

Search for other papers by J Larkin in
Google Scholar
PubMed
Close
,
P Lorigan Department of Medical Oncology, Christie Hospital NHS Foundation Trust, Manchester, UK

Search for other papers by P Lorigan in
Google Scholar
PubMed
Close
,
D Morganstein Department of Endocrinology, Chelsea and Westminster Hospital, London, UK

Search for other papers by D Morganstein in
Google Scholar
PubMed
Close
,
P J Trainer Department of Endocrinology, Christie Hospital NHS Foundation Trust, Manchester, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

Search for other papers by P J Trainer in
Google Scholar
PubMed
Close
, and
the Society for Endocrinology Clinical Committee The Society for Endocrinology, Starling House, 1600 Bristol Parkway North, Bristol, UK

Search for other papers by the Society for Endocrinology Clinical Committee in
Google Scholar
PubMed
Close

Immunotherapy treatment with checkpoint inhibitors (CPI) (CTLA-4 and PD-1 inhibitors) significantly improves survival in a number of cancers. Treatment can be limited by immune-mediated adverse effects including endocrinopathies such as hypophysitis, adrenalitis, thyroiditis and diabetes mellitus. If endocrinopathies (particularly hypocortisolemia) are not recognized early, they can be fatal. The diagnosis and management of endocrinopathies can be complicated by simultaneous multi-organ immune adverse effects. Here, we present Endocrine Emergency Guidance for the acute management of the endocrine complications of checkpoint inhibitor therapy, the first specialty-specific guidance with Endocrinology, Oncology and Acute Medicine input and endorsed by the Society for Endocrinology Clinical Committee. We present algorithms for management: endocrine assessment and management of patients in the first 24 hours who present life-threateningly unwell (CTCAE grade 3–4) and the appropriate management of mild-moderately unwell patients (CTCAE grade 1–2) presenting with features compatible with an endocrinopathy. Other important considerations in relation to hypohysitis and the maintenance of glucocorticoid therapy are discussed.

Open access